Raloxifene

Raloxifene is a nonsteroidal compound classified as a selective estrogen receptor modulator, meaning that it binds estrogen receptors yet produces estrogen-like effects in certain tissues and estrogen-blocking effects in others ^[1][3]. Structurally it belongs to the benzothiophene family, which sets it apart from the triphenylethylene SERMs such as tamoxifen ^[3]. Because its actions depend on the balance of estrogen receptor subtypes present in a given tissue, its overall profile is described as tissue-selective ^[2].

Raloxifene was first approved in the United States in the late 1990s for the prevention of postmenopausal osteoporosis, and its indication was later broadened to treatment of the condition and, in 2007, to reduction of invasive breast cancer risk in postmenopausal women at higher risk ^[2][4]. It is now marketed as a generic medicine in many countries and is taken by mouth ^[1].

Clinically, raloxifene is used to maintain bone mineral density and reduce the risk of vertebral fractures in postmenopausal women, and as a chemopreventive option against estrogen-receptor-positive breast cancer ^[2][4]. Reviews note beneficial effects on serum lipids and a favorable endometrial safety profile compared with some other SERMs, while also highlighting an increased risk of venous blood clots as a recognized concern ^[2][3]. It has been compared with tamoxifen and other agents in the setting of breast cancer prevention ^[4].

Raloxifene is a prescription-only medication supplied as oral tablets ^[1][2]. Its low oral bioavailability and its clearance mainly through glucuronide conjugation distinguish its pharmacokinetics from those of the triphenylethylene SERMs ^[1].

Raloxifene is prescription only and carries a boxed warning for blood clots and stroke. It raises the risk of deep vein thrombosis and pulmonary embolism and can increase the chance of fatal stroke in women who already have or are at high risk for heart disease, so it is stopped before long periods of immobility such as surgery. Common effects are hot flashes, leg cramps, flu like symptoms and ankle swelling. It does not treat menopausal hot flashes and may worsen them. It must not be used in pregnancy or in anyone with a history of clots, and it should be spaced apart from cholestyramine, which blocks its absorption.

Raloxifene is a selective estrogen receptor modulator that also acts as an inhibitor of aldehyde oxidase. It significantly reduces the metabolism of 6-mercaptopurine, a thiopurine immunosuppressant and anticancer drug, by inhibiting aldehyde oxidase-catalyzed oxidation; in vitro studies show 60-70% inhibition of 6-thioxanthine production when raloxifene is present ^[19]. This is a pharmacokinetic interaction where raloxifene impairs the inactivation of thiopurines, potentially increasing their exposure and toxicity.

The interaction is directional; raloxifene affects 6-mercaptopurine metabolism more than 6-mercaptopurine affects raloxifene. Raloxifene is also a substrate of CYP3A4 and P-glycoprotein; inhibitors of these pathways (such as ketoconazole or naringin from grapefruit) can increase raloxifene bioavailability ^[20]. Interactions with other aldehyde oxidase substrates (such as methotrexate or some antimalarials) are plausible but have not been formally studied in humans. The clinical relevance of the 6-mercaptopurine interaction in typical osteoporosis patients (who rarely receive thiopurines) remains uncertain.

Checking a whole stack? Run it through interactions + stacks.

Raloxifene was developed by the American pharmaceutical company Eli Lilly, where it was originally investigated in the 1980s as an antiestrogen for breast cancer under the name keoxifene. Early breast cancer results were unremarkable, but researchers observed that the benzothiophene compound preserved bone density in laboratory models, prompting a strategic redirection toward osteoporosis. This repurposing culminated in approval by the United States Food and Drug Administration in 1997, when it was marketed as Evista for the prevention and treatment of postmenopausal osteoporosis.

A series of major randomized trials, notably MORE, CORE, and RUTH, established both its skeletal benefits and its ability to reduce the risk of invasive estrogen-receptor-positive breast cancer, and in 2007 the STAR trial supported a breast cancer risk-reduction indication. Raloxifene thus became a defining example of the selective estrogen receptor modulator class, prized for acting as an estrogen agonist in bone while opposing estrogen in breast and uterine tissue.

Raloxifene holds a respected place in both bone health and preventive oncology, admired for the elegance of its tissue-selective pharmacology. Clinicians value it for slowing postmenopausal bone loss and reducing vertebral fracture risk while, at the same time, lowering the incidence of invasive breast cancer in higher-risk women, a genuinely dual benefit documented across the MORE, CORE, RUTH, and STAR trials.

Because it does not stimulate the endometrium, it carries a more favorable uterine safety profile than tamoxifen, which makes it attractive for long-term use. Many patients and physicians appreciate that a single drug can address two important concerns of the postmenopausal years. In fairness, its protection is strongest against vertebral rather than hip fractures, and it shares with estrogen an increased risk of venous thromboembolism, so its use is individualized; even so, its combination of bone and breast benefits keeps it a valued option.